Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
8.03
-0.35 (-4.18%)
At close: Oct 23, 2026, 4:00 PM EDT
8.02
-0.01 (-0.12%)
After-hours: Oct 23, 2026, 7:59 PM EDT
Candel Therapeutics Employees
Candel Therapeutics had 55 employees as of December 31, 2025. The number of employees increased by 17 or 44.74% compared to the previous year. That makes Candel Therapeutics the 34,612th largest employer in the world and 4,606th in the United States.
Employees
55
Change (1Y)
17
Growth (1Y)
44.74%
Revenue / Employee
n/a
Profits / Employee
-$1,609,655
Market Cap
614.44M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 55 | 17 | 44.74% |
| Dec 31, 2024 | 38 | -4 | -9.52% |
| Dec 31, 2023 | 42 | -34 | -44.74% |
| Dec 31, 2022 | 76 | 11 | 16.92% |
| Dec 31, 2021 | 65 | 24 | 58.54% |
| Mar 31, 2021 | 50 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Ginkgo Bioworks Holdings | 485 |
| Wave Life Sciences | 317 |
| CorMedix | 191 |
| Prime Medicine | 146 |
| Solid Biosciences | 121 |
| Aura Biosciences | 113 |
| Zevra Therapeutics | 61 |
CADL News
- 2 days ago - Candel Therapeutics Appoints Maria Ostrovsky as General Counsel - GlobeNewsWire
- 2 days ago - Candel Therapeutics initiated with a Buy at Jefferies - TheFly
- 22 days ago - Candel Therapeutics to Present at the SITC 2026 Annual Meeting - GlobeNewsWire
- 23 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Candel announces final phase 2a trial of aglatimagene, valacyclovir - TheFly
- 23 days ago - Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI - GlobeNewsWire
- 24 days ago - Candel Therapeutics announces data from phase 2 PrTK05 trial - TheFly
- 24 days ago - Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer - GlobeNewsWire